姜黄素类似物和多西紫杉醇对人前列腺癌细胞生长的协同作用

doi:10.5246/jcps.2017.11.093

中国药学(英文版) ›› 2017, Vol. 26 ›› Issue (11): 827-833.DOI: 10.5246/jcps.2017.11.093

姜黄素类似物和多西紫杉醇对人前列腺癌细胞生长的协同作用

周代营¹, 丁立¹, 王希^1*, 马娟¹, 黄沃林¹, Susan Goodin², 郑希^3*

1. 广东食品药品职业学院, 广东广州 510520
2. 美国新泽西罗格斯癌症研究所
3. 美国罗格斯大学苏珊Lehman Cullman癌症研究所

收稿日期:2017-07-18 修回日期:2017-10-16 出版日期:2017-11-30 发布日期:2017-10-27
通讯作者: Tel.: +732-445-3400(233); +86-020-28854939, Fax: +732-445-0687; +86-020-37216565, E-mail: xizheng@pharmacy.rutgers.edu; wangx@gdyzy.edu.cn
基金资助:
The National Cancer Institute of China (Grant No. P30-CA072720), the National Natural Science Foundation of China (Grant No. 81272452), and the PhD Start-up Fund of Natural Science Foundation of Guangdong Province, China (Grant No. 2014A030310329).

Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells

Daiying Zhou¹, Li Ding¹, Xi Wang^1*, Juan Ma¹, Wolin Huang¹, Susan Goodin², Xi Zheng^3*

1. Guangdong Food and Drug Vocational College, Guangzhou 510520, China
2. Rutgers Cancer Institute of New Jersey, USA
3. Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, USA

Received:2017-07-18 Revised:2017-10-16 Online:2017-11-30 Published:2017-10-27
Contact: Tel.: +732-445-3400(233); +86-020-28854939, Fax: +732-445-0687; +86-020-37216565, E-mail: xizheng@pharmacy.rutgers.edu; wangx@gdyzy.edu.cn
Supported by:
The National Cancer Institute of China (Grant No. P30-CA072720), the National Natural Science Foundation of China (Grant No. 81272452), and the PhD Start-up Fund of Natural Science Foundation of Guangdong Province, China (Grant No. 2014A030310329).

摘要/Abstract

摘要：

前列腺癌是发生于男性前列腺组织中的恶性肿瘤,近年来我国前列腺癌发病率迅速上升。本文以前列腺癌细胞PC-3细胞株为主要研究对象,联合姜黄素类似物E10和多西紫杉醇作用于前列腺癌细胞,比较其与单独给药的作用效果。结果显示低剂量的姜黄素类似物E10与低剂量的多西紫杉醇联合使用,比两种药物单独高剂量使用更能有效地抑制前列腺癌细胞生长,核转录因子NF-κB信号传导通路和Erk1/2传导通路具有协同作用的机制。研究结果表明联合姜黄素类似物E10和多西紫杉醇对抑制前列腺癌细胞具有一定的协同效应。

关键词: 联合治疗, 前列腺癌, 姜黄素类似物, 多西紫杉醇, 协同效应

Abstract:

Cancer of the prostate gland is a leading cause of death. In the present study, we studied the effects and mechanisms of curcumin analogue E10, docetaxel or their combination on prostate cancer (PC)-3 cells. Treatment of PC-3 cells with E10 or docetaxel resulted in growth inhibition in a concentration-reliant fashion. Combinations of E10 and docetaxel inhibited the growth of PC-3 cells in a synergistic manner. Effects of a combination of E10 and docetaxel were associated with synergistic inhibition of the transcriptional activity of nuclear factor-kappa B (NF-κB), and robust reductions in the levels of B-cell lymphoma-2 (Bcl-2) were found in PC-3 cells treated with a combination of E10 and docetaxel. Our data indicated that the effects of E10 in combination with docetaxel on PC-3 cells were associated with inhibition of NF-κB and Bcl-2. Further studies using suitable animal models are necessary to determine the in vivo effect of this combination.

Key words: Combination treatment, Prostate cancer, Curcumin analogue, Docetaxel, Synergistic effect

中图分类号:

R962

Supporting:

周代营, 丁立, 王希, 马娟, 黄沃林, Susan Goodin, 郑希. 姜黄素类似物和多西紫杉醇对人前列腺癌细胞生长的协同作用[J]. 中国药学(英文版), 2017, 26(11): 827-833.

Daiying Zhou, Li Ding, Xi Wang, Juan Ma, Wolin Huang, Susan Goodin, Xi Zheng. Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(11): 827-833.

参考文献

[1] Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. CA Cancer J. Clin. 2014, 64, 9-29.

[2] Stein, M.N.; Goodin, S.; DiPaola, R.S. Clin. Cancer Res. 2012, 18, 1848-1854.

[3] Thomas, B.M.; Smith, C.; Evans, J.; Button, M.R.; Kumar, S.; Palaniappan, N.; Staffurth, J.; Tanguay, J.S.; Lester, J.F. Med. Oncol. 2013, 30, 1-6.

[4] Kuttan, R.; Bhanumathy, P.; Nirmala, K.; George, M.C. Cancer Lett. 1985, 29, 197-202.

[5] Huang, M.T.; Smart, R.C.; Wong, C.Q.; Conney, A.H. Cancer Res. 1988, 48, 5941-5946.

[6] Leite, K.R.; Chade, D.C.; Sanudo, A.; Sakiyama, B.Y.; Batocchio, G.; Srougi, M. Int. Braz. J. Urol. 2009, 35, 599-607.

[7] Zhou, D.Y.; Zhao, S.Q.; Du, Z.Y.; Zheng, X.; Zhang, K. Oncology Lett. 2016, 11, 4160-4166.

[8] Agrawal, D.K.; Mishra, P.K. Med. Res. Rev. 2010, 30, 818-860.

[9] Anand, P.; Sundaram, C.; Jhurani, S.; Kunnumakkara, A.B.; Aggarwal, B.B. Cancer Lett. 2008, 267, 133-164.

[10] Dhillon, N.; Aggarwal, B.B.; Newman, R.A.; Wolff, R.A.; Kunnumakkara, A.B.; Abbruzzese, J.L.; Ng, C.S.; Badmaev, V.; Kurzrock, R. Clin. Cancer Res. 2008, 14, 4491-4499.

[11] Wei, X.C.; Du, Z.Y.; Zheng, X.; Cui, X.X.; Conney, A.H.; Zhang, K. Eur. J. Med. Chem. 2012, 53, 235-245.

[12] Ikezoe, T.; Hisatake, Y.; Takeuchi, T.; Ohtsuki, Y.; Yang, Y.; Said, J.W.; Taguchi, H.; Koeffler, H.P. Cancer Res. 2004, 64, 7426-7431.

[13] Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Théodore, C.; James, N.D.; Turesson, I. N. Engl. J. Med. 2004, 351, 1502-1512.

[14] Kim, S.M.; Lee, S.Y.; Cho, J.S.; Son, S.M.; Choi, S.S.; Yun, Y.P.; Yoo, H.S.; Oh, K.W.; Han, S.B.; Hong, J.T. Eur. J. Pharmacol. 2010, 631, 1-9.

[15] Ganansia-Leymarie, V.; Bischoff, P.; Bergerat, J.P.; Holl, V. Curr. Med. Chem. Anti Cancer Agents. 2003, 3, 291-306.

[16] Montero, A.; Fossella, F.; Hortobagyi, G.; Valero, V. Lancet Oncol. 2005, 6, 229-239.

[17] Tedesco, K.; Thor, A.; Johnson, D.; Shyr, Y.; Blum, K.; Goldstein, L.; Gradishar, W.; Nicholson, B.; Merkel, D.; Murrey, D. J. Clin. Oncol. 2004, 22, 1071-1077.

[18] Ryan, D.P.; Kulke, M.H.; Fuchs, C.S.; Grossbard, M.L.; Grossman, S.R.; Morgan, J.A.; Earle, C.C.; Shivdasani, R.; Kim, H.; Mayer, R.J. Cancer. 2002, 94, 97-103.

[19] Hasima, N.; Aggarwal, B.B. Int. J. Biochem. Mol. Biol. 2012, 3, 328.

[20] Wei, X.; Zhou, D.; Wang, H.; Ding, N.; Cui, X.X.; Wang, H.; Verano, M.; Zhang, K.; Conney, A.H.; Zheng, X.; Du, Z.Y. Anticancer Res. 2013, 33, 1343-1350.

[21] Zheng, X.; Cui, X.X.; Avila, G.E.; Huang, M.T.; Liu, Y.; Patel, J.; Kong, A.N.; Paulino, R.; Shih, W.J.; Lin, Y.; Rabson, A.B.; Reddy, B.S.; Conney, A.H. Clin. Cancer Res. 2007, 13, 5480-5487.

[22] Zhao, L.; Wientjes, M.G.; Au, J.L. Clin. Cancer Res. 2004, 10, 7994-8004.

[23] McDonnell, T.J.; Troncoso, P.; Brisbay, S.M.; Logothetis, C.; Chung, L.W.; Hsieh, J.T.; Tu, S.M.; Campbell, M.L. Cancer Res. 1992, 52, 6940-6944.

[24] Chen, X.; Liu, Y.; Wu, J.; Huang, H.R.; Du, Z.Y.; Zhang, K.; Zhou, D.Y.; Hang, K.; Goonin, S.; Zheng, X. Cancer Genomics. Proteomics. 2016, 13, 151-160.

[25] Connors, S.K.; Chornokur, G.; Kumar, N.B. Nutr. Cancer. 2012, 64, 4-22.

[26] DiDonato, J.A.; Mercurio, F.; Karin, M. Immunol. Rev. 2012, 246, 379-400.

[27] Ross, J.S.; Kallakury, B.V.; Sheehan, C.E.; Fisher, H.A.; Kaufman, R.P.; Kaur, P.; Gray, K.; Stringer, B. Clin. Cancer Res. 2004, 10, 2466-2472.

[28] Shukla, S.; MacLennan, G.T.; Fu, P.; Patel, J.; Marengo, S.R.; Resnick, M.I.; Gupta, S. Neoplasia. 2004, 6, 390-400.

[29] Fradet, V.; Lessard, L.; Bégin, L.R.; Karakiewicz, P.; Masson, A.M.; Saad, F. Clin Cancer Res. 2004, 10, 8460-8464.

[30] Catz, S.D.; Johnson, J.L. Oncogene. 2001, 20, 7342-7351.

姜黄素类似物和多西紫杉醇对人前列腺癌细胞生长的协同作用

Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

本文评价

[1]	刘雅婕, 王雨, 李佳佳, 许晓庆, 李馨儒. 载阿霉素-芦米司匹多囊脂质体的制备及体内外评价[J]. 中国药学(英文版), 2021, 30(9): 736-742.
[2]	薛钧升, 王思媛, 郝方然, 田秀云, 苏红, 杨亮, 安启明, 郝纯毅, 周田彦. 多巴胺增强舒尼替尼治疗胰腺癌的药效[J]. 中国药学(英文版), 2020, 29(10): 689-700.
[3]	王雪玲, 梁艳琴, 张元, 何冰, 代文兵, 张华, 王学清, 张强. cRGD-DOX自组装纳米粒与贝伐珠单抗联合治疗乳腺癌[J]. 中国药学(英文版), 2019, 28(9): 627-640.
[4]	侯海涛, 宋子冰, 丁婕琴, 位灯国, 胡胜, 翟倩倩, 岳霞丽. 小檗碱通过靶向端粒G-四链体增强舒尼替尼的活性[J]. 中国药学(英文版), 2019, 28(5): 289-297.
[5]	雷冏茜, 从双晨, 宋茂远, 张文茜, 彭光华, 张媛媛, 殷梦雅, 王佳星, 李佳佳, 李馨儒. 用于体外协同效应的阿霉素与去氢骆驼蓬碱脂质体的制备、理化性质与评价[J]. 中国药学(英文版), 2017, 26(9): 666-674.
[6]	李欣, 庞宁, 李骥, 齐宪荣. 两亲性树枝状分子改造的PEG-PLA纳米粒的制备及其表征[J]. 中国药学(英文版), 2017, 26(7): 521-527.
[7]	洪艺华, 刘曈彤, 刘彦君, 吴竞轩, 杨晓改. 钒化合物通过活性氧水平的调节对PTEN表达缺失的前列腺癌细胞发挥更强的抑制作用[J]. 中国药学(英文版), 2017, 26(6): 432-439.
[8]	周代营, 赵肃清, 郑希, 杜志云, 张焜. 哌啶酮类姜黄素类似物的合成及抗肿瘤活性研究[J]. 中国药学(英文版), 2015, 24(8): 524-529.
[9]	朱娜, 赵娜, 雷小平, 凌仰之^*, VenkatechHundratta, AngelaBrodie . 17-(2'-噁唑基)-雄甾体衍生物的合成及其抑制17α-羟化酶/C_17,20-裂解酶的活性[J]. , 2001, 10(1): 14-19.
[10]	茹呈杰, 雷小平, 凌仰之^*, 张礼和, VenkatechHundratta, AngelaBrodie. 17α -羟化酶/C_17,20-裂解酶(P450_17α )抑制剂-17-[(2' -取代的)-4' -嘧啶基]雄烯衍生物的合成及药理活性[J]. , 2001, 10(1): 3-8.